In animal models, SGLT2 inhibitors demonstrate effects on TGF-β-mediated fibrosis, including in murine models with cardiac fibrosis induced by angiotensin II infusion [142] or diabetes [143]. Here, TGFB1 is linked to diabetes mellitus.